Webinar: Pharmacovigilance Submissions Simplified: E2B(R3), FAERS & Safety Reporting Explained

The US FDA has announced that E2B(R3) will become mandatory soon, so now is the time to prepare. Join our experts for an exclusive, complimentary, US‑focused session. In it, we will explore key timelines, FAERS implications, and safety database requirements. Secure your spot today and stay compliant!

Why you should attend
E2B(R3) is not just a format change — it reshapes how ICSRs are structured, validated, and submitted to FAERS. With the mandate coming within the next months, pharmacovigilance and regulatory teams need a fast, practical roadmap to meet the US FDA’s expectations without chaos. This high‑impact briefing helps your team to turn urgency into a clear action plan.

Join our experts, Dr. Andrea Rohatschek Striebel, Priya Krishnan, and Iqra Ali for an energizing, no‑nonsense session packed with actionable guidance drawn from extensive practical experience and US FDA expectations.

Date: 02 June, 2026

Time: 17:00 CEST | 11:00 EDT

This webinar is free and focused on the US regulatory landscape. If you are not sure if you can join live, just register and receive the recording!

What you’ll walk away with

• Clear, prioritized timelines and practical tips for the transition from E2B(R2) to E2B(R3)
• How FAERS reporting and US FDA expectations will change, and what that means for your workflows
• Concrete insights into an innovative safety‑database including AI-functionalities, and how it supports your organization’s way to Effortless Compliance

Register now to secure your spot and beat the last‑minute scramble to meet the E2B(R3) deadline!

Your Speakers:

	Dr. Andrea Rohatschek Striebel Senior Product Manager
	Priya Krishnan Business Consultant
	Iqra Ali Junior Business Consultant